LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Начало・Списък с акции・Essa Pharma Inc

Essa Pharma Inc

Затворен

1.71 1.79

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.68

Максимум

1.71

Ключови измерители
By Trading Economics
Приходи	2.2M -6.4M
EPS	-0.195
Служители	35
EBITDA	-2.2M -8.5M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.3M 75M
Предишно отваряне	-0.08
Предишно затваряне	1.71

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

1.7 / 1.72 Подкрепа & съпротива

Essa Pharma Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.05.2025 г., 22:52 ч. UTC

Печалби

Значими двигатели на пазара

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15.05.2025 г., 20:37 ч. UTC

Топ новини

Печалби

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16.05.2025 г., 00:00 ч. UTC

Пазарно говорене

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15.05.2025 г., 23:47 ч. UTC

Пазарно говорене

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15.05.2025 г., 23:38 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.05.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15.05.2025 г., 23:14 ч. UTC

Топ новини

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15.05.2025 г., 22:46 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15.05.2025 г., 21:58 ч. UTC

Печалби

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15.05.2025 г., 21:24 ч. UTC

Печалби

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15.05.2025 г., 20:56 ч. UTC

Пазарно говорене

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15.05.2025 г., 20:54 ч. UTC

Пазарно говорене

Печалби

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15.05.2025 г., 20:54 ч. UTC

Печалби

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15.05.2025 г., 20:51 ч. UTC

Печалби

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.05.2025 г., 20:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15.05.2025 г., 20:50 ч. UTC

Печалби

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15.05.2025 г., 20:26 ч. UTC

Топ новини

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15.05.2025 г., 20:25 ч. UTC

Печалби

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Essa Pharma Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Essa Pharma Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.7 / 1.72Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.